|
 Repromedix Corp., the leading national diagnostic laboratory for fertility testing, announces today the launch of Plan Ahead, a new blood test that provides an assessment of a woman's egg supply by combining multiple factors including the measurement of ovary-related hormones AMH, Inhibin B, and FSH with innovative and proprietary technology. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs which inevitably declines as a woman ages and her "biological clock ticks." Plan Ahead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age.
"The Plan Ahead test represents an extraordinary advance in fertility diagnostics compared to what has been readily available to the general population," said Dr. Benjamin Leader, Chief Medical Officer. "Many fertility experts view the gold standard of egg supply measurement to be the number of eggs obtained through egg retrieval, an expensive procedure reserved for specialty fertility clinics involving hormone injections and a minimally invasive procedure. The Plan Ahead test offers similar information to the general public via a simple blood test."
A recent survey indicates that over 80% of women between the ages of 25-44 believe that the risk of fertility loss begins at age 35, while many experts believe the risk begins much earlier.
Paul Kowalski, President and VP of Sales, said, "A recent survey indicates that over 80% of women between the ages of 25-44 believe that the risk of fertility loss begins at age 35, while many experts believe the risk begins much earlier. We believe that the Plan Ahead test will provide an important tool for better education and lead to early diagnosis of potential fertility-related issues."
"For more than 14 years, Repromedix has been a pioneer and leader in the field of sophisticated reproductive diagnostics working in partnership with leading reproductive specialists across the country to help people start families," said Dr. Michael Burns, Chief Executive Officer. "Plan Ahead represents a new chapter in Repromedix's history. We are extraordinarily proud to be able to offer this innovative product with clinical validation and endorsement by some of the most well-respected fertility experts in the country. We look forward to the near future when Plan Ahead becomes the standard of care in assessing female fertility."
Repromedix introduces the Plan Ahead test today in Boston, Atlanta, Corona (CA), Norfolk (VA), Denver and Colorado Springs with strategic partnerships with the renowned fertility clinics: Boston IVF, Georgia Reproductive Specialists, The Jones Institute for Reproductive Medicine (VA), Reproductive Medicine & Fertility Center (CO), and the Corona Institute for Reproductive Medicine & Fertility (CA). The Company expects to make the test available in New York, Chicago, Los Angeles, Miami, Fort Lauderdale, Columbia (SC), Raleigh, Indianapolis and Dallas in the near future. The suggested cost of the Plan Ahead test is $350. Women interested in obtaining the Plan Ahead test are encouraged to visit the Company's website: http://www.planaheadtest.com/us.
About Repromedix
Repromedix is the leading national diagnostic laboratory for fertility testing and offers a multifaceted approach to clinical fertility testing that encompasses many medical disciplines including endocrinology, immunology and genetics. Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding the complex problems of reproductive failure. Since its inception in 1993, the company has assisted more than 45,000 patients by performing over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility, and unexplained infertility. Repromedix is a portfolio company of Brook Venture Partners, Ironwood Capital Management, and Brooke Private Equity Advisors.
|
